Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

Clicks: 189
ID: 266709
2016
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Despite a comprehensive search of the literature, the authors failed to find sufficient evidence for providing guidelines on amikacin dosing and therapeutic dru
Reference Key
abi2016journalamikacin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jenkins, Abi;(BSAC Working Party on Therapeutic Drug Monitoring);Thomson, Alison H.;(BSAC Working Party on Therapeutic Drug Monitoring);Brown, Nicholas M.;(BSAC Working Party on Therapeutic Drug Monitoring);Semple, Yvonne;(BSAC Working Party on Therapeutic Drug Monitoring);Sluman, Christine;(BSAC Working Party on Therapeutic Drug Monitoring);MacGowan, Alasdair;(BSAC Working Party on Therapeutic Drug Monitoring);Lovering, Andrew M.;(BSAC Working Party on Therapeutic Drug Monitoring);Wiffen, Phil J.;(BSAC Working Party on Therapeutic Drug Monitoring);
Journal journal of antimicrobial chemotherapy
Year 2016
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.